US Patent for Teverelix LA

Ardana PLC
31 August 2006

                  US PATENT GRANTED TO ARDANA FOR TEVERELIX LA



Edinburgh, UK, 31 August 2006;  Ardana (LSE: ARA), the pharmaceutical company
focused on improving human reproductive health, today announces that it has been
granted a US patent, number 7,098,305, covering the long acting formulation of
its GnRH antagonist, Teverelix (Teverelix LA).



The patent is subject to a US patent term adjustment (i.e. extension), which
means that it is not due to expire in the US until April 2023.



This patent forms part of Ardana's growing intellectual property portfolio
around its research and development activities.



Teverelix is Ardana's lead development compound and is in Phase II clinical
trials in two indications; prostate cancer and benign prostatic hyperplasia,
with Phase I studies ongoing in endometriosis.





For more information contact:


Ardana                                     Financial Dynamics
Maureen Lindsay                            (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550                 Julia Phillips/John Gilbert
                                           Tel: [phone]





About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
outlicensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



  • StriantTM SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with hypogonadism;
  • Teverelix LA, in development for three initial indications (prostate
    cancer, BPH and endometriosis);
  • Testosterone Cream, a trans dermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase II trials;
  • Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.



In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana is listed on the Main Market of the London Stock Exchange.



For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange